Harrow Has Completed The Transfer To Harrow Of The New Drug Application For Triesence, A Synthetic Corticosteroid For Sympathetic Ophthalmia, Temporal Arteritis, Uveitis, And Ocular Inflammatory Conditions
Portfolio Pulse from Benzinga Newsdesk
Harrow Health, Inc. has successfully completed the transfer of the New Drug Application (NDA) for Triesence, a synthetic corticosteroid used to treat various ocular inflammatory conditions, to its own portfolio.
November 29, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harrow Health's completion of the NDA transfer for Triesence may positively impact its stock as it expands its product portfolio with a treatment for eye conditions.
The completion of the NDA transfer for Triesence to Harrow Health is a significant development for the company, indicating growth in its product offerings and potential revenue streams. This news is likely to be viewed positively by investors, as it suggests Harrow Health is actively expanding its market presence in the treatment of ocular diseases. The acquisition of Triesence could lead to increased market share and potentially higher sales, which may result in a short-term positive impact on HROW's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100